GlaxoSmithKline's daily three-in-one inhalation agent ,31 Re-Re-Le is officially launched in China

GlaxoSmithKline (GSK) recently announced that the daily three-in-one inhalation agent for slow-stop strophic treatment, Trelegy® Ellipta ®, has been officially launched in China.Quanre has previously been approved by China's NationalMedicines(http://Regulatory AuthorityThe inhalation preparation is suitable for the treatment of copnaisand(ICS), which contains three pharmaceutical components, the inhaled glucocorticoid (ICS), the long-acting anticholinerandrug(http://(LAMA) and the long-acting beta2 receptor agonist (LABA), and is given daily through GSK's unique ellipta ® dry powder inhalation deviceDrHe Li-Mirror, Head of Medical Affairs and Vice President of GSK China, said they were pleased with the successful launch of Quanre in China, which would allow more patients with COPD to benefit from this world-leading treatmentFull Rere represents an important milestone in the field of COPD treatment, allowing healthcare professionals to treat patients with COPD with a new, single-device triavement agent every dayThe latest clinical studies of the drug show that full repsy can significantly improve lung function, improve quality of life, and significantly reduce acute exacerbation in patients with COPD, compared to an ICS/LABA formulation commonly used in the clinicFurthermore, compared to long-acting anticholinergic drugs/long-acting beta-2 receptor agonists (LAMA/LABA) preparations, Total Rele can significantly reduce the total cause-to-cause mortality rate of patients with COPD5, providing patients with effective treatment options